WeVote
Log In

Bill

Bill

HB 543

AN ACT relating to the use of experimental treatments for life-threatening or severely debilitating illness.

2026 Regular Session Introduced by Vanessa Grossl

Expands access to experimental treatments for patients with life-threatening illnesses while establishing informed consent, safety oversight, and provider responsibilities.

to Health Services (H)
#diseases #drugsandmedicines #healthandmedicalservices #healthcareprofessionals #hospitalsandhealthfacilities #nurses #pharmacists #physicians #research
0
WeVote Research Nonpartisan
Bill Summary · HB 543

Summary of HB 543 (2026 Regular Session, Kentucky)

Purpose and intent

HB 543 seeks to regulate and expand access to experimental treatments for individuals with life-threatening or severely debilitating illnesses. The bill aims to provide a framework for patients to pursue experimental therapies outside standard approved options, while outlining responsibilities for healthcare providers, institutions, and regulators to ensure patient safety, informed consent, and appropriate oversight.

Key provisions and changes

  • Eligibility and scope

    • Applies to patients diagnosed with life-threatening or severely debilitating illnesses.
    • Focuses on access to experimental treatments not yet approved by standard licensure processes, typically in early-phase clinical trials or unapproved therapies under development.

  • Informed consent and counseling

    • Requires comprehensive informed consent prior to any experimental treatment.
    • Mandates disclosure of known risks, potential benefits, alternatives, and the experimental nature of the therapy.
    • May call for counseling or patient education resources to help patients make informed decisions.

  • Physician and provider duties

    • Prohibits coercion or undue influence in seeking experimental treatments.
    • Requires clinicians to assess suitability, including consideration of medical history, likelihood of benefit, and potential harms.
    • May impose duties to monitor patients for adverse events and to report outcomes to a relevant registry or oversight body.

  • Institutional and facility responsibilities

    • Hospitals or clinics offering experimental therapies must adhere to established safety and ethical standards.
    • May require institutional review, ethics committee oversight, or institutional clinical trial processes where applicable.
    • Could address recordkeeping, adverse event reporting, and data privacy considerations.

  • Liability and patient protections

    • Addresses liability standards for providers and facilities when offering experimental treatments, potentially including protections against certain malpractice claims if due care was exercised.
    • May include disclaimers about the experimental status and limits of coverage or reimbursement.
    • Could specify that participation is voluntary and that opting out will not impact eligibility for standard care.

  • Cost and reimbursement considerations

    • May outline how experimental treatments are billed or reimbursed, including whether such therapies are patient-funded, covered by insurance, or eligible for grants or waivers.
    • Could require transparent pricing and clear communication about financial risk.

  • Regulatory and reporting framework

    • Likely to establish reporting requirements to a state health department or an overseeing agency.
    • May create a registry of patients receiving experimental treatments and track outcomes, adverse events, and access disparities.
    • Could set timelines for periodic reporting and audits to ensure compliance.

Who would be affected

  • Patients with life-threatening or severely debilitating illnesses seeking access to experimental therapies.
  • Physicians and other healthcare providers who administer or refer patients to experimental treatments.
  • Hospitals, clinics, and treatment centers offering experimental therapies.
  • Regulatory and oversight bodies within the Kentucky health framework, potentially including state health departments and ethics committees.
  • Insurance carriers and payers managing coverage decisions for experimental treatments.
  • Researchers and trial sponsors involved in early-phase or uncontrolled studies.

Procedural and timeline aspects

  • Introductory status
    • Introduced in the Kentucky House on February 3, 2026. Referral history: To House Committees on Committees and Health Services as of February 2026.
  • Next steps
    • The bill will undergo committee review, potential amendments, and floor consideration. If advanced, it would proceed through the legislative process (debate, possible revisions, and votes) before crossing to the Senate for its own consideration.

Potential impact and considerations

  • The bill could broaden access to experimental options for patients with limited alternatives while embedding safeguards to protect patient safety and informed decision-making.
  • It may clarify expectations for providers regarding duty of care, reporting, and consent, reducing ambiguity in physician-patient engagements around experimental therapies.
  • Financial implications could arise regarding coverage, cost-sharing, and the availability of state or private funding for experimental treatments.
  • The effectiveness of the policy will depend on the specificity of its provisions regarding oversight, data collection, and standardized practices to prevent exploitation or unequal access.

If you’d like, I can tailor this summary to emphasize particular sections (e.g., patient protections, regulatory oversight, or cost implications) or compare HB 543 to similar enacted laws in other states.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.